C.N. Ferreira

Budget Impact Analysis Of Tofacitinib For Rheumatoid Arthritis From The Perspective Of The Brazilian Private Healthcare System

Tofacitinib is an active immunosuppressant: oral administration (unnecessary cold chain) acts as a potent and selective inhibitor of Janus kinase family (JAK), more specifically JAK3 and JAK1, with an important role in cytokine signal transduction that regulates survival, proliferation, differentiation and apoptosis of lymphocytes4. adequate response in monotherapy. may provide multiple benefits for patients, doctors . short half-life. innovative mechanism of action is considered beneficial to patients non-responsive to current therapy DMARD.4

Burden of Disease in Patients with Glaucoma in Brazil.

METHODS: Patients’ self-reported data were collected from 2011-2012 National Health and Wellness Survey (NHWS Kantar Health global self-reported general population survey in healthcare). QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general population). Loss of work/productivity was measured by the validated Work Productivity and Activity Impairment (WPAI) instrument. MRU was measured by healthcare provider, emergency room (ER) visits and hospitalization in the past 6 months. Comparisons were made between respondents who were diagnosed with glaucoma versus respondents without glaucoma (nonglaucoma group). Since glaucoma typically affects adult population, respondents with age 35 and above were included in the analysis.

Economic Burden of Hospitalized Pneumonia from a Private Health Care System Perspective in Brazil

REFERENCES Costs related to pneumonia hospitalization are high and represents a large impact to the total budget expenditures in the Brazilian private healthcare system. Given that the cost for a pneumonia hospitalization is much higher than an average hospitalization, there is a need to better implement pneumonia prevention strategies such as flu and pneumococcal vaccinations and smoking cessation. This study aimed to evaluate the economic burden of hospitalized pneumonia and its associated costs in the Brazilian Private Health System.

Costs of Pneumonia in Patients With Cancer Diagnosis from the Private Health System Perspective in Brazil.

REFERENCES Although the number of pneumonia hospitalization per patient was slightly higher in WCa compared with WoCA patients, the cost per patient and cost per hospitalization was at least 3 times higher in the WCa compared with WoCA patients. The data analyzed show that the oncological therapies represent only about 1.2% of the total cost of expenses of care in oncology, which demonstrates the need for a series of specialized care that is necessary with this type of patient, not just spending with cancer. Given that cancer patients are susceptible to many infections, including pneumonia, strategies to reduce risk of infection should be prioritized. For pneumonia prevention, flu and pneumococcal vaccinations are indicated. Cancer patients are susceptible to infections, including pneumonia, due to immunosuppressive therapies associated with cancer treatment. This study aimed to evaluate the budget impact of pneumonia in patients with previous diagnosed cancer in the Brazilian Private Health System.

Using A HA-CMC Barrier To Avoid Pelvic Or Abdominal Adhesion: Cost-Benefit Advantages In A Private Health Care Setting

Methods: • Costs of care for the treatment of small bowel obstruction were obtained from a • A cost-benefit economic model was developed to compare options of adopting or not the use of HA-CMC barriers during abdominal/pelvic surgeries as a prophylactic way to avoid adhesions in these sites and one of major consequences, the small bowel obstruction. • Collecting data on probabilities on scientific literature for gathering risks of adhesion and other outcomes, as so the ef cacy of the bio-absorbable pellicle to avoid adhesion.

PCV85 Persistence of Patients Treated Hypertensive Medication in PBM With Different Percentages of Financial Subsidy

This method does not account the period between re lling, if the patient acquired the medication su cient for the rst 30 days in a 30 day interval and at that the last day of the period acquired amount of 330 days, it is considered persistent because it will have an MPR = 100% at the end of 12 months, equal to a user who bought the amount equal to 30 days in all intervals steadily. The method MPR value equal or greater than 80% for evaluating the persistence, suggesting that the patient was a few days without drug, and thus showed regular use. OBJECTIVE